Mineralys Therapeutics Announces JAMA Publication of Full Target-HTN Phase 2 Trial Results for Lorundrostat in Uncontrolled and Treatment-Resistant Hypertension

<p>– Lorundrostat, a highly selective aldosterone synthase inhibitor, demonstrated robust, double-digit reduction in systolic blood pressure (BP) with a well-tolerated profile – – Enhanced reduction in systolic BP seen in individuals with elevated body mass index (BMI) – – Robust trial design and results led to lorundrostat being first of new class, aldosterone synthase inhibitors, […]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/mineralys-therapeutics-announces-jama-publication-of-full-target-htn-phase-2-trial-results-for-lorundrostat-in-uncontrolled-and-treatment-resistant-hypertension/">Mineralys Therapeutics Announces JAMA Publication of Full Target-HTN Phase 2 Trial Results for Lorundrostat in Uncontrolled and Treatment-Resistant Hypertension</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>